Cognitive impairment in nondemented Parkinson's disease

Authors


  • Relevant conflicts of interest/financial disclosures: Paolo Barone has previously received honoraria from Merck Serono for lectures and acting in a medical advisory capacity. Dag Aarsland has received honoraria and research support from Merck Serono. David Burn has previously received honoraria from Merck Serono for acting in a medical advisory capacity. Murat Emre has previously received honoraria from Merck Serono for acting in a medical advisory capacity and for lectures. Jaime Kulisevsky has previously received honoraria from Merck Serono for lectures and acting in a medical advisory capacity. Daniel Weintraub has previously received honoraria from Merck Serono for acting in a medical advisory capacity.

  • Full financial disclosures and author roles may be found in the online version of this article.

Abstract

A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early-stage disease and many routine assessment tools lack the sensitivity to detect subtle cognitive dysfunction. Patients with PD and mild CI (MCI) may have a higher risk of developing dementia than cognitively intact PD patients; however, it is not currently known which patients with CI are at increased risk of developing dementia. This review summarizes current knowledge about CI in nondemented PD; it discusses the structural and functional changes associated with CI and addresses areas of unmet needs. We focus on questions that should be addressed in future studies to achieve consensus on its characteristics and definition, pathophysiology, epidemiology, diagnosis and assessment, and treatment and management. © 2011 Movement Disorder Society

Ancillary